HCW Biologics Inc.

As of August 14, 2025, HCW Biologics Inc. is considered overvalued and not a viable investment due to its negative valuation ratios and a year-to-date decline of 74.56%, contrasting sharply with the positive performance of the S&P 500.

As of May 13, 2022, HCW Biologics Inc. is classified as risky and overvalued due to negative financial metrics, including a Price to Book Value of -1.70 and a YTD return of -73.83%, significantly underperforming the S&P 500's 2.44% return.

As of May 9, 2024, HCW Biologics Inc. shows a mildly bullish trend overall, despite conflicting indicators such as bearish daily moving averages and Bollinger Bands.

HCW Biologics Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $2 million as of March 2025. The company has a market cap of $12.79 million and does not pay dividends.

As of Jun 18, HCW Biologics Inc. has a market capitalization of 12.79 million, with net sales of 1.45 million and a net profit of -24.75 million over the last four quarters. The company reported shareholder's funds of -6.77 million and total assets of 30.24 million as of Dec 24.